Top Pharmaceutical ETFs Worth Considering in 2025

The pharmaceutical industry is experiencing robust growth, with projections suggesting the global market will exceed US$1.75 trillion by 2030. For investors seeking exposure to this expanding sector without picking individual stocks, the best pharmaceutical ETFs offer a balanced approach combining diversification with the simplicity of equity trading.

Why Pharmaceutical ETFs Merit Investor Attention

Exchange-traded funds focused on pharma provide several advantages over single-stock investments. They distribute risk across multiple companies spanning oncology, biologics, pain management, and vaccine development. Compared to direct pharmaceutical stock ownership, these funds typically feature lower expense ratios and reduced portfolio volatility while maintaining the liquidity and tax efficiency that ETFs are known for.

Five Leading Pharmaceutical ETF Options

VanEck Pharmaceutical ETF (NASDAQ:PPH) — The Largest by Capital Base

Assets Under Management: US$1.15 billion

Launched in 2011, PPH tracks the MVIS US Listed Pharmaceutical 25 Index with 26 holdings. Its composition emphasizes major integrated pharma players, including Eli Lilly, Novartis, Merck & Company, Novo Nordisk, and McKesson. Analysts recommend this fund for investors seeking tactical sector exposure, though market volatility should be factored into decision-making.

iShares US Pharmaceuticals ETF (ARCA:IHE) — Strong Concentration in Blue-Chip Names

Assets Under Management: US$669.2 million

Established in 2006, IHE concentrates on large-cap U.S. pharmaceutical enterprises through 45 holdings. Johnson & Johnson and Eli Lilly dominate the portfolio, representing approximately half of total assets. Additional significant positions include Merck, Royalty Pharma, and Viatris, making this an ideal choice for investors preferring established market leaders.

Invesco Pharmaceuticals ETF (ARCA:PJP) — Selective Holdings Approach

Assets Under Management: US$299.48 million

PJP, operational since 2005, maintains a more selective strategy by tracking only 31 companies based on rigorous valuation and risk assessments. Eli Lilly, Amgen, Johnson & Johnson, Merck, and AbbVie form its core holdings, appealing to value-conscious investors who appreciate fundamental analysis in fund construction.

State Street SPDR S&P Pharmaceuticals ETF (ARCA:XPH) — Balanced Sector Representation

Assets Under Management: US$189.93 million

XPH, launched in 2006, mirrors the pharmaceutical sub-sector of the S&P Total Market Index, incorporating 52 holdings with relatively uniform weighting. This structure differentiates it from concentrated competitors. Jazz Pharmaceuticals, Tarsus Pharmaceuticals, Eli Lilly, Ligand Pharmaceuticals, and Crinetics Pharmaceuticals represent its leading positions.

KraneShares MSCI All China Health Care Index ETF (ARCA:KURE) — Geographic Diversification Strategy

Assets Under Management: US$95.29 million

KURE provides access to Chinese healthcare equities, tracking 50 mid- and large-cap companies weighted by market capitalization. Launched in 2018, it offers exposure to a distinct geographic market segment, with top holdings including BeOne Medicines, Jiangsu Hengrui Medicine, Innovent Biologics, WuXi Biologics, and Sino Biopharmaceutical.

Selecting the Right Pharmaceutical ETF for Your Portfolio

The best pharmaceutical ETF depends on individual investment objectives. Large-cap focused investors may prefer IHE or PJP, while those seeking broader exposure should consider PPH or XPH. International investors interested in emerging market healthcare opportunities should evaluate KURE separately from its U.S.-based peers.

Data current as of November 2025.